| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 85 | 2025 | 621 | 14.290 |
Why?
|
| Mice, Inbred NOD | 94 | 2025 | 525 | 6.210 |
Why?
|
| Diabetes Mellitus, Experimental | 9 | 2024 | 199 | 3.710 |
Why?
|
| CD8-Positive T-Lymphocytes | 35 | 2023 | 676 | 3.620 |
Why?
|
| Mice | 101 | 2025 | 10849 | 2.410 |
Why?
|
| T-Lymphocytes, Regulatory | 16 | 2025 | 214 | 2.040 |
Why?
|
| Mice, Transgenic | 35 | 2023 | 1281 | 2.030 |
Why?
|
| Disease Models, Animal | 22 | 2024 | 2190 | 1.770 |
Why?
|
| HLA-DQ Antigens | 2 | 2024 | 14 | 1.740 |
Why?
|
| Islets of Langerhans | 26 | 2023 | 279 | 1.740 |
Why?
|
| Animals | 106 | 2025 | 20666 | 1.700 |
Why?
|
| Lymphocyte Activation | 17 | 2020 | 760 | 1.640 |
Why?
|
| Immune Tolerance | 11 | 2022 | 176 | 1.530 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2023 | 642 | 1.420 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2019 | 718 | 1.410 |
Why?
|
| Autoimmunity | 16 | 2024 | 239 | 1.380 |
Why?
|
| Autoantigens | 13 | 2018 | 138 | 1.290 |
Why?
|
| Insulin-Secreting Cells | 9 | 2020 | 190 | 1.270 |
Why?
|
| HLA-A2 Antigen | 6 | 2018 | 64 | 1.270 |
Why?
|
| Autoimmune Diseases | 5 | 2022 | 231 | 1.250 |
Why?
|
| Major Histocompatibility Complex | 6 | 2009 | 88 | 1.170 |
Why?
|
| B-Lymphocytes, Regulatory | 2 | 2017 | 5 | 1.110 |
Why?
|
| Thymus Gland | 5 | 2018 | 233 | 1.070 |
Why?
|
| HLA Antigens | 3 | 2016 | 63 | 1.070 |
Why?
|
| Pancreas | 5 | 2020 | 150 | 1.060 |
Why?
|
| B-Lymphocytes | 9 | 2025 | 574 | 1.050 |
Why?
|
| Antigen-Presenting Cells | 8 | 2010 | 178 | 1.000 |
Why?
|
| B-Lymphocyte Subsets | 7 | 2019 | 47 | 0.990 |
Why?
|
| Interferon-gamma | 6 | 2021 | 568 | 0.890 |
Why?
|
| Myositis | 1 | 2024 | 5 | 0.880 |
Why?
|
| Mice, Knockout | 20 | 2025 | 2110 | 0.860 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2019 | 249 | 0.840 |
Why?
|
| Myocarditis | 1 | 2024 | 66 | 0.820 |
Why?
|
| Mice, Inbred C57BL | 26 | 2025 | 3395 | 0.810 |
Why?
|
| Killer Cells, Natural | 5 | 2009 | 217 | 0.780 |
Why?
|
| Adoptive Transfer | 8 | 2016 | 149 | 0.770 |
Why?
|
| Mice, SCID | 13 | 2020 | 520 | 0.750 |
Why?
|
| Dendritic Cells | 8 | 2013 | 524 | 0.750 |
Why?
|
| Spleen | 11 | 2025 | 484 | 0.740 |
Why?
|
| T-Lymphocytes | 6 | 2021 | 1009 | 0.730 |
Why?
|
| HLA-B Antigens | 2 | 2018 | 13 | 0.720 |
Why?
|
| Natural Killer T-Cells | 4 | 2020 | 29 | 0.700 |
Why?
|
| Neuritis, Autoimmune, Experimental | 1 | 2020 | 1 | 0.690 |
Why?
|
| Nerve Tissue | 1 | 2020 | 6 | 0.690 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 2018 | 144 | 0.690 |
Why?
|
| Cells, Cultured | 14 | 2020 | 2156 | 0.680 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2023 | 287 | 0.650 |
Why?
|
| Rituximab | 2 | 2017 | 87 | 0.630 |
Why?
|
| Immunotherapy | 4 | 2025 | 258 | 0.600 |
Why?
|
| Insulin | 11 | 2023 | 687 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2018 | 12 | 0.600 |
Why?
|
| I-kappa B Proteins | 1 | 2018 | 39 | 0.590 |
Why?
|
| beta 2-Microglobulin | 2 | 2018 | 49 | 0.590 |
Why?
|
| B-Cell Activating Factor | 1 | 2017 | 9 | 0.560 |
Why?
|
| Female | 52 | 2025 | 32722 | 0.560 |
Why?
|
| Clonal Deletion | 4 | 2018 | 11 | 0.550 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2017 | 46 | 0.540 |
Why?
|
| Antigen Presentation | 7 | 2019 | 237 | 0.540 |
Why?
|
| H-2 Antigens | 6 | 2007 | 67 | 0.540 |
Why?
|
| Peptides | 6 | 2019 | 577 | 0.540 |
Why?
|
| Autoantibodies | 8 | 2017 | 183 | 0.510 |
Why?
|
| Cytidine Deaminase | 1 | 2017 | 86 | 0.510 |
Why?
|
| ADP-ribosyl Cyclase 1 | 4 | 2011 | 28 | 0.490 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2015 | 71 | 0.490 |
Why?
|
| Lymph Nodes | 3 | 2025 | 224 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2015 | 58 | 0.480 |
Why?
|
| Lymphocyte Depletion | 6 | 2017 | 99 | 0.480 |
Why?
|
| Humans | 39 | 2025 | 63184 | 0.470 |
Why?
|
| ADP Ribose Transferases | 3 | 2009 | 62 | 0.450 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2019 | 495 | 0.430 |
Why?
|
| Neoplasms | 1 | 2024 | 1360 | 0.420 |
Why?
|
| Cell Differentiation | 10 | 2020 | 1352 | 0.410 |
Why?
|
| Transplantation Tolerance | 4 | 2006 | 65 | 0.410 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2009 | 46 | 0.400 |
Why?
|
| Carrier Proteins | 1 | 2017 | 706 | 0.390 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 780 | 0.390 |
Why?
|
| Antigens, CD20 | 1 | 2011 | 14 | 0.370 |
Why?
|
| Receptors, Calcitriol | 1 | 2011 | 34 | 0.370 |
Why?
|
| Hypocalcemia | 1 | 2011 | 19 | 0.370 |
Why?
|
| Sjogren's Syndrome | 3 | 2020 | 24 | 0.370 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2008 | 119 | 0.360 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2011 | 9 | 0.360 |
Why?
|
| Radiation Chimera | 4 | 2012 | 58 | 0.350 |
Why?
|
| Immunity, Mucosal | 2 | 2021 | 52 | 0.350 |
Why?
|
| Glucose-6-Phosphatase | 6 | 2020 | 15 | 0.350 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1537 | 0.340 |
Why?
|
| Transgenes | 4 | 2010 | 187 | 0.340 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2025 | 59 | 0.330 |
Why?
|
| HLA-A Antigens | 2 | 2007 | 9 | 0.320 |
Why?
|
| Mice, Congenic | 8 | 2016 | 22 | 0.320 |
Why?
|
| Chromosome Mapping | 5 | 2019 | 289 | 0.320 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 217 | 0.310 |
Why?
|
| Cell Movement | 4 | 2005 | 451 | 0.300 |
Why?
|
| Genetic Markers | 5 | 2012 | 128 | 0.300 |
Why?
|
| Calcium | 1 | 2011 | 573 | 0.290 |
Why?
|
| Alleles | 6 | 2019 | 449 | 0.280 |
Why?
|
| Antigens, CD1 | 1 | 2007 | 41 | 0.270 |
Why?
|
| Genetic Loci | 2 | 2019 | 115 | 0.270 |
Why?
|
| Gene Deletion | 2 | 2006 | 308 | 0.270 |
Why?
|
| Membrane Glycoproteins | 4 | 2020 | 669 | 0.260 |
Why?
|
| Th1 Cells | 3 | 2019 | 175 | 0.260 |
Why?
|
| CD27 Ligand | 2 | 2020 | 3 | 0.260 |
Why?
|
| Male | 27 | 2021 | 29724 | 0.250 |
Why?
|
| Interleukin-4 | 2 | 2013 | 141 | 0.250 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2019 | 181 | 0.250 |
Why?
|
| Clone Cells | 7 | 2008 | 114 | 0.240 |
Why?
|
| Adenovirus E3 Proteins | 1 | 2005 | 2 | 0.230 |
Why?
|
| Enterovirus B, Human | 1 | 2005 | 17 | 0.230 |
Why?
|
| Enterovirus Infections | 1 | 2005 | 12 | 0.230 |
Why?
|
| Peptide Fragments | 4 | 2013 | 411 | 0.230 |
Why?
|
| Islets of Langerhans Transplantation | 4 | 2008 | 176 | 0.230 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2020 | 109 | 0.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2008 | 349 | 0.220 |
Why?
|
| Cytokines | 4 | 2019 | 936 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 158 | 0.220 |
Why?
|
| Clonal Anergy | 4 | 2019 | 23 | 0.220 |
Why?
|
| Graft Survival | 6 | 2008 | 290 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 5 | 2021 | 894 | 0.210 |
Why?
|
| CRISPR-Cas Systems | 2 | 2018 | 356 | 0.210 |
Why?
|
| Inflammation | 5 | 2020 | 1145 | 0.210 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 166 | 0.210 |
Why?
|
| Nervous System Autoimmune Disease, Experimental | 1 | 2003 | 2 | 0.210 |
Why?
|
| Paralysis | 1 | 2003 | 17 | 0.200 |
Why?
|
| Receptors, Interferon | 1 | 2003 | 21 | 0.200 |
Why?
|
| Interleukins | 2 | 2021 | 80 | 0.200 |
Why?
|
| Cell Death | 1 | 2004 | 285 | 0.200 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 182 | 0.200 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2020 | 3 | 0.200 |
Why?
|
| Proteins | 5 | 2011 | 751 | 0.200 |
Why?
|
| Adenoviridae | 1 | 2003 | 121 | 0.200 |
Why?
|
| Genome, Viral | 1 | 2003 | 136 | 0.190 |
Why?
|
| STAT1 Transcription Factor | 3 | 2021 | 35 | 0.190 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 177 | 0.190 |
Why?
|
| CD4 Antigens | 3 | 2020 | 149 | 0.180 |
Why?
|
| Mycoses | 1 | 2021 | 46 | 0.180 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 2021 | 1 | 0.180 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2021 | 4 | 0.180 |
Why?
|
| Lacrimal Apparatus | 1 | 2020 | 3 | 0.180 |
Why?
|
| Microbiota | 1 | 2023 | 129 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2017 | 984 | 0.170 |
Why?
|
| Thymocytes | 1 | 2020 | 21 | 0.170 |
Why?
|
| 4-1BB Ligand | 1 | 2020 | 1 | 0.170 |
Why?
|
| Candida albicans | 1 | 2021 | 72 | 0.170 |
Why?
|
| Pancreas, Exocrine | 1 | 2020 | 12 | 0.170 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2020 | 103 | 0.160 |
Why?
|
| Serum Albumin, Human | 1 | 2019 | 7 | 0.160 |
Why?
|
| Amino Acid Sequence | 5 | 2014 | 1597 | 0.160 |
Why?
|
| Protein Precursors | 1 | 2019 | 83 | 0.160 |
Why?
|
| Genetic Variation | 3 | 2015 | 384 | 0.160 |
Why?
|
| CD11c Antigen | 1 | 2019 | 8 | 0.150 |
Why?
|
| Receptors, Cell Surface | 3 | 2013 | 431 | 0.150 |
Why?
|
| Gene Targeting | 1 | 2019 | 77 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 2 | 2013 | 229 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 371 | 0.140 |
Why?
|
| CD40 Antigens | 2 | 2016 | 61 | 0.140 |
Why?
|
| CD8 Antigens | 2 | 2008 | 54 | 0.140 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Galactosylceramides | 2 | 2009 | 11 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 192 | 0.140 |
Why?
|
| Ampicillin | 1 | 2017 | 12 | 0.140 |
Why?
|
| Bone Marrow Cells | 4 | 2016 | 238 | 0.140 |
Why?
|
| Macrophages | 5 | 2007 | 1039 | 0.140 |
Why?
|
| 5'-Nucleotidase | 1 | 2017 | 2 | 0.140 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2017 | 6 | 0.140 |
Why?
|
| Gram-Positive Bacteria | 1 | 2017 | 36 | 0.140 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2017 | 15 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 30 | 0.140 |
Why?
|
| Prediabetic State | 2 | 2011 | 53 | 0.130 |
Why?
|
| Specific Pathogen-Free Organisms | 3 | 2019 | 42 | 0.130 |
Why?
|
| STAT4 Transcription Factor | 1 | 2016 | 8 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2020 | 3035 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2017 | 160 | 0.130 |
Why?
|
| Peripherins | 2 | 2014 | 14 | 0.130 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2017 | 83 | 0.130 |
Why?
|
| Quantitative Trait Loci | 2 | 2025 | 75 | 0.130 |
Why?
|
| Intestines | 1 | 2017 | 167 | 0.130 |
Why?
|
| Skin Transplantation | 3 | 2006 | 156 | 0.120 |
Why?
|
| Antigens, CD | 3 | 2013 | 347 | 0.120 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2015 | 6 | 0.120 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 1184 | 0.120 |
Why?
|
| Immune System | 1 | 2016 | 130 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 543 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2008 | 149 | 0.120 |
Why?
|
| Lectins, C-Type | 2 | 2013 | 90 | 0.120 |
Why?
|
| Crosses, Genetic | 3 | 2012 | 110 | 0.120 |
Why?
|
| Haplotypes | 2 | 2007 | 131 | 0.120 |
Why?
|
| Retinal Degeneration | 1 | 2015 | 27 | 0.120 |
Why?
|
| Antibodies | 3 | 2013 | 182 | 0.120 |
Why?
|
| Flow Cytometry | 4 | 2009 | 669 | 0.120 |
Why?
|
| Transplantation, Heterologous | 2 | 2005 | 229 | 0.110 |
Why?
|
| Dog Diseases | 1 | 2015 | 60 | 0.110 |
Why?
|
| Chromosomes, Mammalian | 2 | 2012 | 34 | 0.110 |
Why?
|
| Solubility | 2 | 2005 | 179 | 0.110 |
Why?
|
| Cholera Toxin | 1 | 2013 | 7 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 434 | 0.100 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 371 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 236 | 0.100 |
Why?
|
| Immunity, Innate | 4 | 2007 | 796 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 57 | 0.100 |
Why?
|
| Crystallography, X-Ray | 1 | 2014 | 433 | 0.100 |
Why?
|
| Antigens | 1 | 2013 | 147 | 0.100 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 1615 | 0.100 |
Why?
|
| Disease Progression | 3 | 2014 | 1166 | 0.100 |
Why?
|
| Glycine Plasma Membrane Transport Proteins | 1 | 2012 | 1 | 0.100 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 72 | 0.090 |
Why?
|
| Homeostasis | 3 | 2020 | 370 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 3 | 2020 | 129 | 0.090 |
Why?
|
| Mice, Inbred DBA | 3 | 2012 | 84 | 0.090 |
Why?
|
| Joints | 1 | 2012 | 33 | 0.090 |
Why?
|
| Retroelements | 1 | 2012 | 45 | 0.090 |
Why?
|
| Cell Communication | 1 | 2012 | 131 | 0.090 |
Why?
|
| Mutagenesis, Insertional | 1 | 2012 | 89 | 0.090 |
Why?
|
| Calcium, Dietary | 1 | 2011 | 29 | 0.090 |
Why?
|
| Neuromuscular Junction | 1 | 2012 | 78 | 0.090 |
Why?
|
| CD40 Ligand | 5 | 2016 | 158 | 0.090 |
Why?
|
| Plasma Cells | 1 | 2011 | 53 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 788 | 0.090 |
Why?
|
| Glutamate Decarboxylase | 3 | 2013 | 22 | 0.090 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 41 | 0.090 |
Why?
|
| Asthma | 1 | 2015 | 440 | 0.090 |
Why?
|
| Genetic Linkage | 1 | 2011 | 96 | 0.090 |
Why?
|
| Animals, Genetically Modified | 1 | 2012 | 290 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2011 | 97 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 130 | 0.090 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 137 | 0.090 |
Why?
|
| Genes, MHC Class I | 2 | 2018 | 27 | 0.090 |
Why?
|
| Immunoglobulins | 1 | 2010 | 77 | 0.090 |
Why?
|
| Peptide Library | 3 | 2008 | 37 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 19 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2011 | 98 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 140 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 113 | 0.080 |
Why?
|
| Lysosomes | 1 | 2011 | 167 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 1998 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 455 | 0.080 |
Why?
|
| B7-1 Antigen | 1 | 2009 | 73 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 1464 | 0.080 |
Why?
|
| Graft Rejection | 3 | 2005 | 293 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2009 | 82 | 0.080 |
Why?
|
| Salivary Glands | 2 | 2020 | 46 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2008 | 181 | 0.080 |
Why?
|
| Genotype | 1 | 2011 | 664 | 0.080 |
Why?
|
| Immunologic Techniques | 1 | 2008 | 11 | 0.070 |
Why?
|
| Muramidase | 2 | 2010 | 46 | 0.070 |
Why?
|
| Lymphopenia | 2 | 2004 | 35 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 327 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 424 | 0.070 |
Why?
|
| Chimera | 1 | 2007 | 42 | 0.070 |
Why?
|
| Molecular Mimicry | 2 | 2004 | 32 | 0.070 |
Why?
|
| Hemocyanins | 1 | 2006 | 23 | 0.070 |
Why?
|
| Neurons, Afferent | 1 | 2006 | 17 | 0.070 |
Why?
|
| TRPV Cation Channels | 1 | 2006 | 20 | 0.070 |
Why?
|
| Rats | 3 | 2010 | 1981 | 0.070 |
Why?
|
| Species Specificity | 1 | 2007 | 336 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 2 | 2006 | 139 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2007 | 167 | 0.060 |
Why?
|
| Transplantation Chimera | 2 | 2020 | 40 | 0.060 |
Why?
|
| Cricetinae | 1 | 2006 | 368 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2007 | 178 | 0.060 |
Why?
|
| Homozygote | 2 | 2003 | 124 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2005 | 85 | 0.060 |
Why?
|
| Point Mutation | 1 | 2006 | 166 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 674 | 0.060 |
Why?
|
| Cell Aggregation | 1 | 2005 | 21 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2005 | 203 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2020 | 1514 | 0.060 |
Why?
|
| Cell Survival | 1 | 2006 | 573 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 4 | 2016 | 869 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2004 | 90 | 0.060 |
Why?
|
| Genetic Carrier Screening | 1 | 2004 | 15 | 0.050 |
Why?
|
| Paleontology | 1 | 2004 | 2 | 0.050 |
Why?
|
| RNA Editing | 1 | 2004 | 23 | 0.050 |
Why?
|
| Fossils | 1 | 2004 | 7 | 0.050 |
Why?
|
| Hominidae | 1 | 2004 | 7 | 0.050 |
Why?
|
| Incidence | 2 | 2005 | 1374 | 0.050 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 32 | 0.050 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2023 | 7 | 0.050 |
Why?
|
| Brain | 1 | 2012 | 1552 | 0.050 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2003 | 13 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2003 | 188 | 0.050 |
Why?
|
| Eye | 1 | 2003 | 54 | 0.050 |
Why?
|
| Glutens | 1 | 2023 | 15 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2004 | 120 | 0.050 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2003 | 47 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2004 | 319 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2004 | 297 | 0.050 |
Why?
|
| Apoptosis | 2 | 2006 | 1075 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 94 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 285 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 2037 | 0.050 |
Why?
|
| Heterozygote | 1 | 2002 | 169 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 280 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2004 | 494 | 0.050 |
Why?
|
| Time Factors | 4 | 2017 | 3757 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2021 | 22 | 0.050 |
Why?
|
| Proteolysis | 1 | 2023 | 145 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2014 | 611 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 537 | 0.040 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2021 | 2 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2003 | 261 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2013 | 35 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2016 | 200 | 0.040 |
Why?
|
| Sex | 1 | 2020 | 5 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2021 | 17 | 0.040 |
Why?
|
| Kinetics | 1 | 2003 | 764 | 0.040 |
Why?
|
| Peripheral Tolerance | 1 | 2020 | 3 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 24 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2021 | 22 | 0.040 |
Why?
|
| CD5 Antigens | 1 | 2020 | 18 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2020 | 25 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 30 | 0.040 |
Why?
|
| Acinar Cells | 1 | 2020 | 8 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2020 | 56 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 614 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 2019 | 34 | 0.040 |
Why?
|
| Lymphopoiesis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2003 | 1147 | 0.040 |
Why?
|
| Animals, Congenic | 1 | 2019 | 4 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 195 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 526 | 0.040 |
Why?
|
| Self Tolerance | 2 | 2010 | 20 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 97 | 0.040 |
Why?
|
| Deoxyribonucleases | 1 | 2019 | 32 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2020 | 188 | 0.040 |
Why?
|
| Phenotype | 2 | 2017 | 1199 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 152 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 290 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 894 | 0.040 |
Why?
|
| Animal Husbandry | 1 | 2017 | 10 | 0.030 |
Why?
|
| Decontamination | 1 | 2017 | 12 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2017 | 61 | 0.030 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2016 | 8 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 112 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2016 | 63 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2017 | 146 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2008 | 243 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 2008 | 176 | 0.030 |
Why?
|
| Aging | 2 | 2016 | 746 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 765 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 416 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Blindness | 1 | 2015 | 41 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 263 | 0.030 |
Why?
|
| Histocompatibility Antigen H-2D | 2 | 2004 | 6 | 0.030 |
Why?
|
| Exome | 1 | 2015 | 77 | 0.030 |
Why?
|
| Epitopes | 2 | 2008 | 296 | 0.030 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2014 | 18 | 0.030 |
Why?
|
| Peritoneum | 1 | 2014 | 29 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 50 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 692 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 325 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2013 | 13 | 0.030 |
Why?
|
| Cholera Vaccines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 376 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2014 | 198 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 312 | 0.030 |
Why?
|
| Disease Resistance | 1 | 2012 | 24 | 0.020 |
Why?
|
| Genome | 1 | 2015 | 275 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 400 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 491 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 369 | 0.020 |
Why?
|
| Grooming | 1 | 2012 | 4 | 0.020 |
Why?
|
| Maze Learning | 1 | 2012 | 55 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2012 | 30 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 120 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2011 | 51 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2011 | 74 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 204 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4672 | 0.020 |
Why?
|
| Insulinoma | 1 | 2010 | 5 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 39 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2010 | 68 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 84 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 6227 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 52 | 0.020 |
Why?
|
| Camelids, New World | 1 | 2009 | 7 | 0.020 |
Why?
|
| Sharks | 1 | 2009 | 7 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 332 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 16734 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2009 | 38 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2009 | 133 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 346 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 300 | 0.020 |
Why?
|
| Anxiety | 1 | 2012 | 423 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 701 | 0.020 |
Why?
|
| Substance P | 1 | 2006 | 38 | 0.020 |
Why?
|
| Capsaicin | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 182 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 267 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2006 | 40 | 0.020 |
Why?
|
| Corticosterone | 1 | 2006 | 23 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2006 | 42 | 0.020 |
Why?
|
| NAD | 1 | 2006 | 53 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2005 | 37 | 0.020 |
Why?
|
| Microspheres | 1 | 2005 | 56 | 0.010 |
Why?
|
| Eosinophils | 1 | 2005 | 46 | 0.010 |
Why?
|
| Myotonin-Protein Kinase | 1 | 2004 | 3 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2005 | 273 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 2004 | 3 | 0.010 |
Why?
|
| Peroxynitrous Acid | 1 | 2004 | 5 | 0.010 |
Why?
|
| Chromones | 1 | 2004 | 19 | 0.010 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 14331 | 0.010 |
Why?
|
| Abatacept | 1 | 2004 | 65 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 59 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 199 | 0.010 |
Why?
|
| Morpholines | 1 | 2004 | 88 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2004 | 84 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 171 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2003 | 16 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2003 | 32 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2003 | 9 | 0.010 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2003 | 5 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2003 | 37 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 17474 | 0.010 |
Why?
|
| Retinal Pigments | 1 | 2003 | 5 | 0.010 |
Why?
|
| Iris | 1 | 2003 | 3 | 0.010 |
Why?
|
| Aqueous Humor | 1 | 2003 | 4 | 0.010 |
Why?
|
| Anterior Chamber | 1 | 2003 | 4 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 199 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 411 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2003 | 48 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 156 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 2609 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 130 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2006 | 483 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 174 | 0.010 |
Why?
|
| fas Receptor | 1 | 2003 | 57 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 207 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 103 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 99 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 878 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 313 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 225 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 937 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2003 | 161 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 639 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1608 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 1393 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 5621 | 0.010 |
Why?
|